MALT1 Antibody

1. Cellular metabolism constrains innate immune responses in preterm infants due to perturbations in the expression of PPARgamma, MALT1, DDIT4, and most of the cytokines. PMID:30446641
2. this first report show that MALT1 integrates several T-cell activation pathways and indirectly controls gamma-chain receptor dependent survival, to impact on T-cell expansion PMID:29359407
3. These findings suggested that cleavage at R781 of MALT1 played a role in the survival of activated B-cell like diffuse large B-cell lymphoma cells. PMID:29953499
4. MALT1 and TRAF6 cooperatively interact with CARMA1-BCL10 filaments and form CARMA1-BCL10-MALT1-TRAF6 signalosome. PMID:29382759
5. The results suggest that the involvement of MALT1 in DNA damage-induced NF-kappaB is through the recruitment of TRAF6. PMID:28717989
6. A missense mutation in mucosa-associated lymphoid tissue lymphoma translocation 1 gene (MALT1) was identified in a family with siblings with IPEX-Like Syndrome. MALT1 deficiency should now be considered as a possible cause of IPEX-like syndrome associated with immunodeficiency. PMID:27253662
7. Thrombin-mediated MALT1 protease activation triggers acute disruption of endothelial barrier integrity via CYLD cleavage. PMID:27681433
8. Authors utilized transcriptomic data and experimental evidences to prove that miR-181d was a novel regulator of NFkappaB signaling pathway by directly repressing MALT1, leading to induced PN markers and reduced MES genes. PMID:28286260
9. Taken together, this present study indicates that miR-649 promotes herpes simplex virus type 1 replication through regulation of the MALT1-mediated antiviral signaling pathway and suggests a promising target for antiviral therapies. PMID:27813118
10. These results demonstrate a key role for the proteolytic activity of MALT1 in PEL, and provide a rationale for the pharmacological targeting of MALT1 in PEL therapy. PMID:27538487
11. MALT1 deficiency or pharmacological inhibition of MALT1 catalytic activity inhibits pathogenic mutant CARD14-induced cytokine and chemokine expression in human primary keratinocytes. PMID:27113748
12. CARD14/MALT1-mediated signaling in keratinocytes has a role in psoriasis [review] PMID:27939769
13. Psoriasis mutations disrupt CARD14 autoinhibition promoting BCL10-MALT1-dependent NF-kappaB activation PMID:27071417
14. Studies indicate that t(11;18)(q21;q21) translocation involves MALT1 (MALT lymphoma translocation protein 1) gene. PMID:26386283
15. Targeting MALT1 proteolytic activity in autoimmune disease and B-cell lymphoma might not be a successful strategy. (Review) PMID:26787500
16. Data show that Bruton tyrosine kinase (BTK)inhibitor Ibrutinib augments MALT lymphoma associated translocation protein (MALT1) inhibition by S-Mepazine in CD79 antigen mutant activated B cell-subtype (ABC) of diffuse large B cell lymphoma (DLBCL). PMID:26540570
17. TCR-induced alternative splicing augments MALT1 scaffolding to enhance downstream signalling and to promote optimal T-cell activation. PMID:27068814
18. MALT1 protease activity has a central role in keratinocyte immunity PMID:26767426
19. Data show that caspase recruitment domain-containing protein 11/B-cell CLL/lymphoma 10/mucosa-associated lymphoid tissue lymphoma translocation gene 1 signaling drives lymphoproliferation through NF-kappa B and c-Jun N-terminal kinase activation. PMID:26668357
20. MALT1-dependent NF-kappaB activation is crucial for the development of EGFR-associated solid-tumor progression PMID:25982276
21. Backbone Assignment of the MALT1 Paracaspase by Solution NMR. PMID:26788853
22. The MALT1-mediated HOIL-1 cleavage provides a gain-of-function mechanism that is involved in the negative feedback regulation of NF-kappaB signaling. PMID:26573773
23. The MALT1 is a key player in the activation of the NF-kappa B upon antigen receptor stimulation and lymphocyte activation. PMID:26716947
24. Comparative analysis of the active site suggests that paracaspases constitute one of the several subclasses of metacaspases that have evolved several times independently. PMID:26377317
25. An overview of the present understanding of MALT1's function is presented. [review] PMID:26507244
26. By regulating linear ubiquitination, MALT1 is both a positive and negative pleiotropic regulator of the human canonical NF-kappaB pathway. PMID:26525107
27. MALT1 uses multiple strategies to ensure NF-kappaB activation and target gene expression. (Review) PMID:25996250
28. data demonstrate that MALT1 ubiquitination is critical for the engagement of CBM and IKK complexes, thereby directing platelet signals to the NF-kappaB pathway. PMID:25748427
29. API2-MALT1 induces paracaspase-mediated cleavage of the tumour suppressor protein LIMA1. PMID:25569716
30. The strongest hypermethylation signal in type 2 diabetes mellitus is in the promoter of the MALT1 gene, involved in insulin and glycemic pathways, and related to taurocholate levels in blood. PMID:25502755
31. Absence of the carcinoma cell-specific mutation suggests that the inactivation of MALT1 expression but not the mutation promotes oral carcinoma progression PMID:22752732
32. This is q review of the understanding of MALT1 function and regulation, and the development of small molecule MALT1 inhibitors for therapeutic applications. PMID:25285878
33. MALT1 auto-proteolysis is essential for NF-kappaB-dependent gene transcription in activated lymphocytes. PMID:25105596
34. Overexpression of CARMA-BCL10-MALT in T-ALL may contribute to the constitutive cleavage and inactivation of A20, which enhances NF-kappaB signaling and may be related to T-ALL pathogenesis. PMID:25384343
35. MALT1 exerts its effect upon immune response through the initiation of cellular miR-2909 RNomics. PMID:25500259
36. The MALT1 and MALT1-V1 variant expression level was downregulated in rheumatoid arthritis patients. PMID:24971370
37. In the crystal structure of human MALT1casp-Ig3 in complex with the tricyclic phenothiazine derivative thioridazine the inhibitor is bound in a hydrophobic pocket far from the active site. PMID:23946259
38. This review highlights the recent advances in the normal and disease-related functions of MALT1 PMID:24004675
39. Combined immunodeficiency associated with homozygous MALT1 mutations. PMID:24332264
40. our study implicates RIP1 ubiquitination as a critical component of API2-MALT1-dependent lymphomagenesis PMID:23770847
41. Taken together, loss of MALT1 expression alters keratin expression and enhances proliferation of carcinoma cells, and may progress oral carcinomas into the advanced state. PMID:23799590
42. Glutamate 549 at the dimerization interface is required for the formation of the enzymatically active, monoubiquitinated form of MALT1. PMID:23977204
43. Structure-guided mutagenesis confirmed the observed interfaces in Bcl10 filament assembly and MALT1 activation in vitro and NF-kappaB activation in cells. PMID:24074955
44. Overexpression of MALT1 partially rescues HECTD3 depletion-induced apoptosis. PMID:23358872
45. USP2a plays an important role in TCR signaling by deSUMOylating TRAF6 and mediating TRAF6-MALT1 interaction PMID:23264041
46. observations demonstrate MALT1 represses genes activating the aggressive phenotype of carcinoma cells, and MALT1 acts as a tumour suppressor and the loss of expression stimulates oral carcinoma progression PMID:23778523
47. Report t(14;18)(q32;q21) involving IGH-MALT1 in extranodal diffuse large B-cell lymphomas of the breast and testis. PMID:23018871
48. monoubiquitination of MALT1 is essential for its catalytic activation and is therefore a potential target for the treatment of ABC-DLBCL and for immunomodulation. PMID:23416615
49. A selected lead compound, MI-2, featured direct binding to MALT1 and suppression of its protease function. PMID:23238016
50. These phenothiazines selectively inhibit cleavage activity of recombinant and cellular MALT1 by a noncompetitive mechanism. PMID:23238017

Show More

Hide All

HGNC: 6819

UNIGENE: Hs.601217

KEGG: hsa:10892

STRING: 9606.ENSP00000319279

OMIM: 604860